Date: 2016-05-31
Type of information: Development agreement
Compound: patch-test tool based on the Viaskin® technology platform
Company: DBV Technologies (France) Nestlé Health Science (France)
Therapeutic area: Allergic diseases - Diagnostic - Technology - Services
Type agreement: development commercialisation
Action mechanism:
Disease: MAG1C, Cow’s Milk Protein Allergy (CMPA) in infants
Details: * On May 31, 2016, Nestlé Health Science announced that it has entered into a strategic collaboration with DBV Technologies, aimed at developing and bringing to market DBV’s innovative patch-test tool for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants. DBV will leverage its proprietary Viaskin® technology platform to develop an innovative, ready-to-use, standardized atopy patch-test. This new diagnostic test is expected to be submitted for approval to regulatory authorities worldwide by 2021.
Today, CMPA is often missed in the primary care settings due to the non-specific nature of symptoms associated with the condition, such as eczema, reflux, constipation, diarrhea, crying and others. In 2015, Nestlé Health Science made a first step forward in addressing this difficulty through the Cow’s Milk-related Symptom Score (CoMiSS®) awareness tool, developed by leading international experts to help healthcare professionals earlier recognize and assess symptoms that may be related to CMPA in infants and young children.
In the future, DBV’s patch-test will enable early and accurate diagnosis of the condition, leading to early nutritional intervention, thereby creating a strong fit with Nestlé Health Science’s nutritional solutions that helps meet the needs of babies and children with food allergies and intolerances (Althéra®, Alfaré®, Alfamino®).
Financial terms: Under the terms of the agreement, DBV will be eligible to receive up to €100 million in development, registration and commercial milestones, including an upfront payment of €10 million. DBV will be responsible for performing development activities up through a pivotal Phase III clinical program, following which Nestlé Health Science has the exclusive right to commercialize the product globally, if approved. DBV will pay for all development-related costs of MAG1C, including a worldwide clinical program, as well as manufacturing costs. If MAG1C is successfully manufactured by DBV, the company will receive a supply price with a mark-up from Nestlé Health Science. In addition, Nestlé Health Science will pay to DBV tiered royalties on global product sales. This new diagnostic test is expected to be submitted for approval to regulatory authorities worldwide by 2021.
Latest news:
